10-Q: APX Acquisition Corp. I Reports Net Loss for Q1 2024, Faces Going Concern Uncertainty Amid Business Combination Efforts

APX Acquisition Corp. I reported a net loss of $2.25 million for the quarter ended March 31, 2024, and is working towards a business combination with OmnigenicsAI while facing uncertainties about its ability to continue as a going concern.

Summary

• APX Acquisition Corp. I, a blank check company, reported a net loss of $2,249,261 for the three months ended March 31, 2024.
• This loss is significantly higher than the net loss of $192,362 reported for the same period in 2023.
• The company's operating expenses for the quarter were $1,305,094, compared to $920,696 in the prior year.
• Interest income from the Trust Account was $813,333, a decrease from $1,455,804 in 2023.
• The company recognized an unrealized loss of $1,757,500 due to changes in the fair value of warrant liabilities.
• As of March 31, 2024, APX Acquisition Corp. I had $568 in cash and a working capital deficit of $2,417,430.
• The company is pursuing a business combination with OmnigenicsAI Corp, but faces a deadline of December 9, 2024, to complete the transaction.
• Management expresses substantial doubt about the company's ability to continue as a going concern due to the mandatory liquidation if a business combination is not completed.
• The company has extended the termination date multiple times by depositing funds into the Trust Account, reaching a total of nine one-month extensions.
• The company has issued a promissory note for working capital, with $1,048,365 outstanding as of March 31, 2024.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to the company's significant net loss, working capital deficit, limited cash reserves, and the uncertainty surrounding its ability to continue as a going concern. The need for multiple extensions and the potential for liquidation further contribute to the negative sentiment.

Positives

• The company is actively pursuing a business combination with OmnigenicsAI Corp.
• The company has secured extensions to the termination date, providing more time to complete a business combination.
• The company has an agreement with Theo I SCSp for a backstop agreement of up to $10,000,000.

Negatives

• The company reported a significant net loss of $2.25 million for Q1 2024.
• The company has a substantial working capital deficit of $2.42 million.
• The company has very limited cash reserves, with only $568 on hand as of March 31, 2024.
• Management expresses substantial doubt about the company's ability to continue as a going concern.
• The company faces a mandatory liquidation if a business combination is not completed by December 9, 2024.
• The company has material weaknesses in its internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is uncertain due to limited cash and the need to complete a business combination by December 9, 2024.
• Failure to complete the business combination with OmnigenicsAI Corp will result in mandatory liquidation.
• The company's financial condition is weak, with a significant working capital deficit and limited cash reserves.
• Material weaknesses in internal control over financial reporting could lead to errors in financial reporting.
• Global economic conditions and geopolitical instability could adversely affect the company's ability to consummate a business combination.
• The company received a deficiency letter from Nasdaq for failing to maintain a minimum of $1,000,000 in aggregate market value of its outstanding warrants.

Future Outlook

The company is focused on completing its business combination with OmnigenicsAI Corp by December 9, 2024, but faces uncertainty regarding its ability to continue as a going concern if the transaction is not completed.

Management Comments

• Management believes that the Company will not have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing.
• Management has determined that the mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution as well as insufficient cash flows raises substantial doubt about the Company's ability to continue as a going concern.

Industry Context

The report reflects the challenges faced by many SPACs in the current market, including difficulties in completing business combinations and maintaining sufficient working capital. The need for extensions and the potential for liquidation are common themes in the SPAC industry.

Comparison to Industry Standards

• Given the current market conditions, APX Acquisition Corp. I's financial situation is not unique among SPACs.
• Many SPACs are facing challenges in finding suitable targets and completing business combinations within the allotted timeframe.
• The high redemption rates and the need for extensions are common issues in the SPAC market.
• Comparable companies such as Gores Metropoulos II, Inc. and Churchill Capital Corp IV have faced similar challenges in completing their business combinations.
• The outcome of APX Acquisition Corp. I will depend on its ability to successfully complete the business combination with OmnigenicsAI Corp.

Related Party Transactions

• The company issued Founder Shares to the Sponsor for $25,000.
• The company may reimburse an affiliate of the Sponsor up to $10,000 per month for office space and administrative support.
• The company issued an unsecured promissory note to Bioceres LLC, an indirect shareholder of OmnigenicsAI Corp.

Stakeholder Impact

• Shareholders face the risk of liquidation if the business combination is not completed.
• Employees of APX Acquisition Corp. I face uncertainty about their future employment.
• The target business, OmnigenicsAI Corp, faces uncertainty about the completion of the business combination.
• Creditors of APX Acquisition Corp. I face the risk of non-payment if the company liquidates.

Next Steps

• The company needs to complete its business combination with OmnigenicsAI Corp by December 9, 2024.
• The company needs to address the material weaknesses in its internal control over financial reporting.
• The company needs to regain compliance with Nasdaq listing requirements.
• The company needs to secure additional funding to meet its working capital needs.

Key Dates

Keywords

business combination, SPAC, OmnigenicsAI, liquidation, warrants, redemption, going concern, Trust Account, APX Acquisition Corp. I, financial statements